Nelociguat
Nelociguat has been in phase II clinical trials by Bayer for the treatment of erectile dysfunction and heart failure. However, no recent development has been reported.
General Information
Update Date：2015-12-22
- Drug Name：
- Nelociguat
- Research Code：
- BAY-60-4552; BAY-604552; BAY-98-7081; Bay-987081
- Trade Name：
- MOA：
- Soluble guanylate cyclase (sGC) activator
- Indication：
- Erectile dysfunction (ED); Heart failure
- Status：
- Phase II (Pending)
- Company：
- Bayer (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-12-22
|
Molecular Weight | 408.39 | ||||||||||||
| Formula | C19H17FN8O2 | |||||||||||||
| CAS No. | 625115-52-8 (Nelociguat); | |||||||||||||
| Chemical Name | Carbamic acid, N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-, methyl ester | |||||||||||||
| Nelociguat （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||